GO
Loading...

Vertex Pharmaceuticals Inc

More

  • Top Undervalued Pharma Stock: Analyst Monday, 29 Apr 2013 | 1:23 PM ET

    One biotech name has the best upside potential for 2013, pharmaceutical analyst Barbara Ryan says.

  • Stocks End Up, But Log Worst Weekly Drop in 2013 Friday, 19 Apr 2013 | 4:32 PM ET

    Stocks reversed a two-day slump to close out the week on a positive note, with the S&P 500 rebounding after finishing below it 50-day moving average for the first time this year, but all three major averages still logged their worst weekly drop this year.

  • Futures Pare Gains on Earnings; GE, MCD Lower Friday, 19 Apr 2013 | 8:26 AM ET

    U.S. stock index futures trimmed some gains Friday, with major averages poised to post their worst weekly declines this year, as investors reacted to the latest wave of earnings reports.

  • Early Movers: GE, MDLZ, DELL & More Friday, 19 Apr 2013 | 7:35 AM ET

    Check out which companies are making headlines before the bell on Friday:

  • After-Hours Buzz: GOOG, IBM, MSFT & More Thursday, 18 Apr 2013 | 4:42 PM ET

    Check out which companies are making headlines after the bell Thursday:

  • Final Trade: Your First Move for Friday, April 19 Thursday, 18 Apr 2013 | 1:39 PM ET

    The "Fast Money" traders share their final trades of the day.

  • Cramer: 3 Stocks on the Speculative Side Tuesday, 2 Apr 2013 | 6:27 PM ET

    Cramer thinks any one of the following 3 stocks deserves a spot inside a properly diversified portfolio.

  • Generics Brought Down Common Drug Prices Tuesday, 5 Mar 2013 | 11:15 AM ET

    Spending on drugs to treat common diseases fell 1.5 percent among customers who receive prescription benefits through commercial insurers.

  • Biotech's a Buy, but Hold Off on HMOs: Fund Manager Wednesday, 9 Jan 2013 | 2:02 PM ET

    Rock bottom interest rates will likely boost key stocks in the biotechnology sector, but Obamacare will dampen prospects for HMO shares.

  • 13 Biotech Stock Predictions for 2013 Wednesday, 2 Jan 2013 | 7:55 AM ET

    TheStreet.com offers up 13 biotech predictions for 2013.

  • *3rd quarter net loss 27 cents a share. Nov 1- Vertex Pharmaceuticals Inc reported a net loss for the third quarter on Thursday with results hurt by fast-declining sales of its Incivek hepatitis C drug, as the company turned its attention to developing a next generation of treatments for the serious liver disease.

  • UPDATE 2-Vertex posts loss as hepatitis drug sales fall Thursday, 1 Nov 2012 | 10:52 PM ET

    Nov 1- Vertex Pharmaceuticals Inc reported a net loss for the third quarter on Thursday with results hurt by declining sales of its Incivek hepatitis C drug, as the company turned its attention to developing a next generation of treatments for the serious liver disease.

  • *3rd quarter net loss 27 cents a share. Nov 1- Vertex Pharmaceuticals Inc reported a net loss for the third quarter on Thursday with results hurt by fast-declining sales of its Incivek hepatitis C drug, as the company turned its attention to developing a next generation of treatments for the serious liver disease.

  • --Abiomed Inc rescheduled second-quarter conference call to Nov. 1 at 8 am Eastern Time. --Accelrys Inc rescheduled third-quarter results to Oct. 31, after market. Its conference call will be held on Nov. 1, 9.30 am Eastern Time.

  • --Acorda Therapeutics Inc: rescheduled third-quarter financial results and conference call to Oct. 31 from Oct. 30. --Advent Software Inc reschedules third-quarter results and conference call to Oct. 30. --AGCO Corp rescheduled third-quarter results to Oct 31, 8 am Eastern Time from Oct. 30.

  • --Martha Stewart Living Omnimedia Inc rescheduled third-quarter results to Nov. 1 from Oct. 30. --Vertex Pharmaceuticals Inc rescheduled third-quarter 2012 earnings and conference call to after markets close on Nov. 1 from Oct. 29. --The McGraw-Hill Companies Inc rescheduled third-quarter earnings and conference call to Nov. 2 from Oct. 31.

  • Abbott Labs rises on hepatitis C drug data Monday, 15 Oct 2012 | 11:48 AM ET

    NEW YORK-- Abbott Laboratories said Monday that its experimental hepatitis C drug regimen cured 99 percent of patients in a midstage study with the most common and hardest-to-treat type of the disease. Abbott shares rose $2.77, or 4 percent, to close at $72.05 Monday.

  • Oct 11- Vertex Pharmaceuticals Inc:. *Data from phase 2 combination study of vx-809 and ivacaftor in people with. cystic fibrosis who have the most common genetic mutation presented.

  • Stocks to Watch: JNJ, LLY, EW & More Tuesday, 9 Oct 2012 | 8:08 AM ET

    Take a look at some of Tuesdays morning movers.

  • Oct 2- Vertex Pharmaceuticals Inc:. *Lazard raises Vertex Pharmaceuticals Inc price target to $75 from. Reuters Station users, click. 1568.